Back to catalog

Allergy · Infectious Disease · Internal Medicine

PEN-FAST Penicillin Allergy Decision Rule calculator

Enter the published formula inputs below to calculate and interpret this score.

Clinical inputs

Result

Anyone can run this calculator. Sign in to save, favourite, or send the result.

0

PEN-FAST 0 — very low risk

Band: PEN-FAST 0 — very low risk

Interpretation. PEN-FAST 0 — very low risk

Suggested management. Very low risk of true penicillin allergy on testing.

PEN-FAST Penicillin Allergy Decision Rule: 0 — PEN-FAST 0 — very low risk. Interpretation: PEN-FAST 0 — very low risk What to do: Very low risk of true penicillin allergy on testing. Inputs: Patient reports a penicillin allergy: false; Allergy ≤5 years ago (+2): false; Anaphylaxis, angioedema, or severe cutaneous adverse reaction (+2): false; Treatment was required for the allergic reaction (+1): false Source: Trubiano JA et al. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med. DOI: 10.1001/jamainternmed.2020.0229. PMID: 32176248. Scope: PEN-FAST among patients reporting penicillin allergy — timing ≤5 years (+2), anaphylaxis/angioedema or severe cutaneous adverse reaction (+2), treatment required for the index reaction (+1); total 0–5; 0 very low risk of positive allergy test. (2020)

Ruqelo is AI and can make mistakes. Check important information.

Clinical inputs

  • Patient reports a penicillin allergy
  • Allergy ≤5 years ago (+2)
  • Anaphylaxis, angioedema, or severe cutaneous adverse reaction (+2)
  • Treatment was required for the allergic reaction (+1)

Primary source

Trubiano JA et al. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med. DOI: 10.1001/jamainternmed.2020.0229. PMID: 32176248. Scope: PEN-FAST among patients reporting penicillin allergy — timing ≤5 years (+2), anaphylaxis/angioedema or severe cutaneous adverse reaction (+2), treatment required for the index reaction (+1); total 0–5; 0 very low risk of positive allergy test. (2020)

View source